Health · 1 sources covering this

STAT+: A key European clinical trial registry lacks complete and timely results, an analysis finds

A new analysis found that results for less than half of the clinical studies registered in a key European database were reported within the required time frame.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·3h ago
STAT+: A key European clinical trial registry lacks complete and timely results, an analysis finds
A new analysis found that results for less than half of the clinical studies registered in a key European database were reported within the required time frame.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/ded6017de9eda3da30a50fc22368f384b28eb9f5"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: A key European clinical trial registry lacks complete and timely results, an analysis finds"></iframe>

STAT+: A key European clinical trial registry lacks complete and timely results, an analysis finds

How 1 sources are covering this

STAT+: A key European clinical trial registry lacks complete and timely results, an analysis finds

More from Health

STAT+: Trump’s obesity drug plan creates a temporary Medicare program that may be hard to end

Covid vaccination cut risk of adverse heart events, large study finds

STAT+: Lilly’s Ajax acquisition may have been worth it

STAT+: Pharmalittle: We’re reading about Pfizer’s emergency penicillin program, a Sanofi diabetes drug, and more

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: A key European clinical trial registry lacks complete and timely results, an analysis finds

More from Health

STAT+: Trump’s obesity drug plan creates a temporary Medicare program that may be hard to end

Covid vaccination cut risk of adverse heart events, large study finds

STAT+: Lilly&#8217;s Ajax acquisition may have been worth it

STAT+: Pharmalittle: We&#8217;re reading about Pfizer&#8217;s emergency penicillin program, a Sanofi diabetes drug, and more

Reader

Trust & legal

Across the network

STAT+: Lilly’s Ajax acquisition may have been worth it

STAT+: Pharmalittle: We’re reading about Pfizer’s emergency penicillin program, a Sanofi diabetes drug, and more